Ghrelin and Gut Motility: The Digestive Role
Gut Peptide Hormones
28 amino acids
Ghrelin, a 28-amino-acid acylated peptide from the gastric fundus, accelerates gastric emptying and stimulates phase III migrating motor complex contractions through the GHS-R1a receptor, establishing it as one of the most potent prokinetic peptides identified.
Chen et al., Endocrine Reviews, 2009
Chen et al., Endocrine Reviews, 2009
View as imageGhrelin is best known as the hunger hormone, the 28-amino-acid peptide released from the stomach that tells the brain to eat. But the same molecule has a second role that precedes its appetite function: ghrelin is a potent prokinetic agent that stimulates gastric emptying, initiates the migrating motor complex (MMC) that sweeps the gut clean between meals, and coordinates motility across the stomach and small intestine.[1] These prokinetic properties have made ghrelin and its receptor agonists candidates for treating gastroparesis, postoperative ileus, and functional dyspepsia. Ghrelin shares 36% structural homology with motilin, the established peptide regulator of gut motility, and their receptors share significant amino acid sequence similarity, yet they operate through distinct signaling pathways. For a complete map of gut peptide signaling, see our pillar article on motilin and gut peptide hormones.
Key Takeaways
- Ghrelin accelerates gastric emptying of both solid and liquid meals in healthy humans and gastroparetic patients by stimulating antral contractions through the GHS-R1a receptor
- The prokinetic effects operate through the enteric nervous system, requiring intact vagal cholinergic neurons, capsaicin-sensitive afferent fibers, and excitatory tachykininergic motor neurons (Perboni and Bhutta, 2010)
- Ghrelin and motilin share 36% amino acid homology and their receptors share sequence similarity, but ghrelin's prokinetic effects are mediated exclusively through GHS-R1a, not the motilin receptor (Depoortere, 2003)
- In streptozotocin-induced diabetic mice, ghrelin and GHRP-6 reversed gastroparesis by restoring gastric emptying rates toward normal (Qiu et al., 2008)
- Relamorelin, a synthetic ghrelin agonist, accelerated gastric emptying in phase II gastroparesis trials and advanced to phase III development (Zatorski et al., 2017)
- Ghrelin's prokinetic and appetite-stimulating effects are mediated by different neural pathways, raising the possibility of separating motility benefits from hunger side effects
Ghrelin's prokinetic mechanism
Ghrelin stimulates gut motility through a multi-step neural pathway that has been dissected primarily through animal pharmacology studies.
Chen et al. (2009) reviewed the evidence and established that ghrelin's prokinetic effects require three components working in sequence: the GHS-R1a receptor on vagal afferent neurons, central processing through the dorsal vagal complex, and efferent vagal cholinergic output to the gut wall.[1]
The mechanism proceeds through the enteric nervous system. Perboni and Bhutta (2010) reviewed how ghrelin activates capsaicin-sensitive afferent neurons that relay signals to the brainstem, which then sends vagal efferent signals to the myenteric plexus in the gut wall. The final motor output involves excitatory tachykininergic motor neurons that contract gastric smooth muscle.[2] Blocking any step in this chain, from vagotomy to capsaicin desensitization to tachykinin receptor antagonism, abolishes the prokinetic response.
This neural pathway distinguishes ghrelin's prokinetic action from its endocrine effects. Ghrelin's appetite stimulation works through hypothalamic circuits involving neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons. The motility pathway is anatomically separate, operating through brainstem vagal circuits. This separation has clinical implications: it may be possible to design ghrelin agonists that preferentially activate motility pathways without excessive appetite stimulation.
Ghrelin versus motilin: related but distinct
Ghrelin and motilin are structural relatives with overlapping but distinct functions. Depoortere (2003) characterized the relationship: the two peptides share 36% amino acid sequence homology, and their receptors (GHS-R1a and the motilin receptor) share significant structural similarity.[3]
Despite this homology, their prokinetic mechanisms differ:
- Motilin initiates phase III of the MMC from the upper GI tract during fasting, primarily through direct activation of smooth muscle cells and enteric neurons. Erythromycin acts as a motilin receptor agonist and is the basis for its off-label use as a prokinetic.
- Ghrelin also stimulates MMC-like contractions but through the GHS-R1a receptor exclusively. Its prokinetic activity is not mediated through the motilin receptor, even though the two receptors share structural features.
Depoortere et al. (2005) compared the gastroprokinetic effects of ghrelin, GHRP-6, and motilin directly in rats. All three stimulated gastric motility, but through receptor-specific pathways: ghrelin and GHRP-6 through GHS-R1a, and motilin through its own receptor. The co-administration of ghrelin and motilin did not produce additive effects, suggesting the two pathways converge on common downstream motor outputs.[4]
Kitazawa et al. (2005) tested both peptide and non-peptide ghrelin agonists on gastric motility in mice, both in vivo (gastric emptying of a solid meal) and in vitro (isolated stomach strips). Ghrelin agonists consistently accelerated gastric emptying in vivo but had minimal direct effect on isolated stomach strips, confirming that the prokinetic activity requires intact neural pathways rather than direct smooth muscle stimulation.[5]
For more on the related peptide cholecystokinin (CCK) and its opposing role in gut motility, see our dedicated article. Stengel and Tache (2011) reviewed how ghrelin and CCK interact at the level of the brainstem to coordinate the transition between fasting motility (promoted by ghrelin) and fed-state motility (modulated by CCK).[6]
Gastroparesis: the clinical opportunity
Gastroparesis, delayed gastric emptying without mechanical obstruction, affects an estimated 4% of the US population and has limited treatment options. The prokinetic properties of ghrelin have made it a logical therapeutic target for this condition.
Qiu et al. (2008) tested ghrelin and GHRP-6 in streptozotocin-induced diabetic mice with gastroparesis. Both peptides restored gastric emptying rates toward normal values. Ghrelin at 100 nmol/kg increased gastric emptying from 37% (diabetic controls) to 58% (approaching the 65% rate in non-diabetic controls). GHRP-6 produced similar effects.[7] The same group (Qiu et al., 2008) characterized the gastric motor effects in more detail, showing that ghrelin increased antral contraction amplitude and frequency in diabetic mice.[8]
Ogiso et al. (2011) reviewed the evidence for ghrelin in functional dyspepsia, another condition characterized by impaired gastric motility. They noted that plasma ghrelin levels are altered in patients with functional dyspepsia, and that exogenous ghrelin administration improved gastric accommodation and reduced symptoms in preliminary human studies.[9]
Shin and Bhakta (2015) reviewed therapeutic applications of ghrelin agonists specifically in gastroparesis and concluded that the class showed consistent gastroprokinetic effects across preclinical models and early clinical trials, with the primary challenge being selectivity for motility effects over metabolic effects (appetite, GH release).[10]
Relamorelin and clinical development
The most clinically advanced ghrelin agonist for motility indications is relamorelin, a synthetic pentapeptide ghrelin receptor agonist.
Zatorski et al. (2017) reviewed the clinical development pipeline for ghrelin receptor agonists in gastroparesis and functional dyspepsia. Relamorelin demonstrated significant acceleration of gastric emptying in phase II trials in diabetic gastroparesis, with improvements in both gastric emptying rate and symptom scores compared to placebo. The drug advanced to phase III development.[11]
The clinical development of ghrelin agonists for gastroparesis has been complicated by several factors. The same receptor that mediates prokinetic effects also stimulates appetite and GH release. In gastroparesis patients who may already have difficulty managing weight or blood glucose (particularly in diabetic gastroparesis), additional appetite stimulation and GH-driven insulin resistance are unwanted effects. Relamorelin's development trajectory has reflected this challenge: strong gastroprokinetic efficacy accompanied by side effects that limit the therapeutic window.
De Smet et al. (2009) reviewed motilin and ghrelin as prokinetic drug targets and noted that while both peptide systems offer prokinetic potential, the ideal drug would selectively activate gut motility pathways without stimulating appetite, GH release, or metabolic effects.[12] Achieving this selectivity remains an unsolved pharmacological challenge.
Beyond the stomach: small intestinal and colonic effects
Ghrelin's prokinetic effects extend beyond gastric emptying to include small intestinal transit and, in some models, colonic motility.
Wang et al. (2015) showed that extrinsic ghrelin administered into the paraventricular nucleus of the hypothalamus increased small intestinal motility in rats through central GHS-R1a activation, demonstrating that ghrelin can drive intestinal motility through both peripheral and central pathways.[13]
Tsukamoto et al. (2024) identified a sex-dependent component to ghrelin's colonic prokinetic effects. A ghrelin agonist acting through the lumbosacral defecation center showed different efficacy in male versus female rats, suggesting that ghrelin-mediated colonic motility is influenced by sex hormones.[14] This finding is relevant because gastroparesis and functional constipation both show female predominance, and sex-specific responses to prokinetic agents could explain differential treatment outcomes.
Ghrelin and the gastroprotective connection
Ghrelin has effects on the gut beyond motility. Brzozowski et al. (2006) demonstrated that ghrelin has gastroprotective properties, protecting gastric mucosa against ischemia-reperfusion injury through a prostaglandin/cyclooxygenase-dependent pathway. This protective effect is mediated through GHS-R1a and operates independently of the prokinetic mechanism.[15]
The combination of prokinetic and gastroprotective properties makes ghrelin unusual among prokinetic agents. Most prokinetic drugs (metoclopramide, domperidone, erythromycin) do not protect the gastric mucosa, and some may contribute to mucosal irritation at higher doses.
For more on how gut peptides coordinate digestive function, see our articles on secretin and gastrin and VIP. The complete peptide signaling network is covered in every peptide hormone your gut produces.
What the evidence does not resolve
The link between gastric emptying and symptom improvement is inconsistent. Ghrelin agonists reliably accelerate gastric emptying in clinical trials, but symptom improvement does not always correlate with emptying rate changes. This suggests gastroparesis symptoms may involve more than delayed emptying.
Tachyphylaxis with chronic use has not been adequately characterized. The GHRP/ghrelin pathway shows reduced GH responses with sustained activation (as seen with hexarelin and GHRP-6). Whether the prokinetic effects similarly attenuate with chronic dosing is not well-established.
Separation of prokinetic from metabolic effects remains pharmacologically challenging. No ghrelin agonist in clinical development has achieved prokinetic selectivity without appetite stimulation and GH release.
The role of des-acyl ghrelin (the unacylated form, which does not bind GHS-R1a) in gut motility is unclear. Des-acyl ghrelin constitutes the majority of circulating ghrelin and may have its own gut effects through unidentified receptors.
The Bottom Line
Ghrelin is a potent prokinetic peptide that accelerates gastric emptying and stimulates the migrating motor complex through the GHS-R1a receptor, enteric nervous system, and vagal cholinergic pathways. Despite sharing structural homology with motilin, ghrelin's prokinetic effects operate through a distinct receptor and neural pathway. Ghrelin agonists have shown consistent gastroprokinetic efficacy in gastroparesis models and early clinical trials, with relamorelin advancing to phase III. The primary clinical challenge is achieving prokinetic selectivity without triggering appetite stimulation, GH release, and metabolic side effects. Ghrelin also has gastroprotective properties independent of its motility effects.